Novartis Splits Drugs Business As Pharma Division CEO David Epstein Leaves In Latest Management Shake-Up
Novartis is splitting its pharmaceuticals division into two business units, one focused on cancer medicines and the second on the Swiss company's other drugs, it said Tuesday, its latest management shake-up within months.
David Epstein, division head and chief executive of Novartis Pharmaceuticals, will leave the company to "explore new challenges," Novartis said in a statement.